| Gap junction |
KEGG |
52 |
3.00E-07 |
1.12E-04 |
| Ras |
PANTHER |
8 |
9.81E-07 |
2.75E-04 |
| Long-term depression |
KEGG |
32 |
1.38E-06 |
3.09E-04 |
| Lipid metabolism |
PANTHER |
78 |
2.02E-06 |
4.11E-04 |
| Zinc finger protein |
PANTHER |
19 |
3.77E-06 |
6.49E-04 |
| Neoplasms, fibrous tissue |
MetaCore |
26 |
6.79E-06 |
1.01E-03 |
| Neoplasms, connective and soft tissue |
MetaCore |
144 |
3.39E-05 |
4.22E-03 |
| Cell adhesion_Platelet-endothelium-leucocyte interactions |
MetaCore |
76 |
5.22E-05 |
6.15E-03 |
| Autoimmune diseases |
MetaCore |
189 |
5.58E-05 |
6.25E-03 |
| Mucinoses |
MetaCore |
12 |
7.72E-05 |
8.23E-03 |
| Plasmacytoma |
MetaCore |
60 |
8.87E-05 |
9.03E-03 |
| Blood protein disorders |
MetaCore |
63 |
9.47E-05 |
9.22E-03 |
| B-cell- and antibody-mediated immunity |
PANTHER |
33 |
1.21E-04 |
1.13E-02 |
| Multiple myeloma/paraproteinemias |
MetaCore |
58 |
1.57E-04 |
1.15E-02 |
| Hemorrhagic disorders |
MetaCore |
104 |
1.44E-04 |
1.15E-02 |
| Anterior/posterior patterning |
PANTHER |
22 |
1.59E-04 |
1.15E-02 |
| Mesoderm development |
PANTHER |
221 |
1.66E-04 |
1.16E-02 |
| Neuroendocrine tumors |
MetaCore |
207 |
2.00E-04 |
1.32E-02 |
| B cell receptor signaling pathway |
KEGG |
34 |
2.18E-04 |
1.36E-02 |
| Macrophage-mediated immunity |
PANTHER |
46 |
2.65E-04 |
1.60E-02 |
| Regulation of metabolism |
MetaCore |
135 |
3.64E-04 |
2.09E-02 |
| Cell adhesion_Attractive and repulsive receptors |
MetaCore |
125 |
4.89E-04 |
2.70E-02 |
| Slit-Robo signaling |
MetaCore |
29 |
5.06E-04 |
2.70E-02 |
| Interleukin signaling pathway |
PANTHER |
66 |
4.96E-04 |
2.70E-02 |
| Arachidonic acid production |
MetaCore |
7 |
7.20E-04 |
3.75E-02 |
| Segment specification |
PANTHER |
31 |
8.43E-04 |
4.20E-02 |
| Sarcoma |
MetaCore |
116 |
8.91E-04 |
4.29E-02 |
| Vascular hemostatic disorders |
MetaCore |
73 |
9.01E-04 |
4.29E-02 |
| Carcinoma, neuroendocrine |
MetaCore |
27 |
1.11E-03 |
4.87E-02 |
